Artemisinin Said Losing Effectiveness In Treating Southeast Asia Malaria
This article was originally published in PharmAsia News
Executive SummaryThe main ingredient in malaria drugs relied on in Southeast Asia is reported to be losing its ability to stop the spread of the disease. A newly published study says artemisinin, the active pharmaceutical ingredient in anti-malaria drugs considered the most effective, now takes nearly twice as long as before to clean out the parasites behind the disease. Studies were carried out in Cambodia and Thailand. The decline in effectiveness is similar to that experienced for chloroquine and fansidar half a century ago. (Click here for more
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.